Study of Heart Rhythm Problems in Adults Treated with BTK Inhibitors or Venetoclax for Blood Cancers

What this Trial Is About

Researchers are studying the effects of Bruton tyrosine kinase inhibitors BTKi on the heart, specifically looking at the risk of abnormal heart rhythms that can lead to sudden death in people treated for certain blood cancers like chronic lymphocytic leukemia. This observational study aims to better understand how BTKi affect heart health, comparing patients starting or already on BTKi to those receiving venetoclax, another therapy not known to increase cardiac risks. Participants include those planning to start or currently taking BTKi or venetoclax. Those not yet on BTKi will have two clinic visits one before starting treatment and one about six months later, while those already on BTKi will have one required visit. Various heart tests will be done including physical exams, blood and saliva collection, heart activity monitoring with chest stickers, echocardiograms, exercise stress tests or stress MRI scans, and possibly wearing a heart monitor device at home. During the study, participants will have assessments to detect heart arrhythmias and monitor heart function. Follow-up phone calls will continue yearly for up to three years to check for heart symptoms or changes related to therapy. Researchers will track cardiac events, sudden death, test results, and other factors like medication use and genetic markers to understand risks. The main outcome is monitoring arrhythmogenic effects and sudden death within the first year of BTKi therapy.

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax